Pulmatrix announced that it will halt a Phase 2b trial of PUR1900 dry powder itraconazole (Pulmazole) in patients with allergic bronchopulmonary aspergillosis (ABPA) that was initiated in February 2023. The company says that the move is part of an amended agreement with Cipla, which has been partnered with Pulmatrix on development of PUR1900 for the treatment of ABPA since 2019.
With the amended agreement, Cipla has acquired development and commercialization rights to PUR1900 for ABPA in all markets outside of the US and will now take over the development program, the company said. Pulmatrix will be entitled 2% royalties on net sales of Pulmazole in the “Cipla territory.”
Pulmatrix CEO Ted Raad commented, “Stopping the Ph2b study, along with other cost-savings measures, is expected to extend Pulmatrix’s cash runway into Q1 2026. . . . Pulmatrix focus will be on maximizing shareholder value by pursuing strategic alternatives for the company while it winds down the Ph2b study for PUR1900. We are confident in Cipla’s ability to develop PUR1900 for the benefit of patients in markets where there is significant unmet need and a faster path to commercialization.”
Read the Pulmatrix press release.
